Pre-End-Stage Renal Disease Hemoglobin Variability Predicts Post-End-Stage Renal Disease Mortality in Patients Transitioning to Dialysis. by Sumida, Keiichi et al.
UC Irvine
UC Irvine Previously Published Works
Title
Pre-End-Stage Renal Disease Hemoglobin Variability Predicts Post-End-Stage Renal Disease 
Mortality in Patients Transitioning to Dialysis.
Permalink
https://escholarship.org/uc/item/2dg130mt
Journal
American journal of nephrology, 46(5)
ISSN
0250-8095
Authors
Sumida, Keiichi
Diskin, Charles Dyer
Molnar, Miklos Z
et al.
Publication Date
2017
DOI
10.1159/000484356
License
CC BY 4.0
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Pre-ESRD Hemoglobin Variability Predicts Post-ESRD Mortality 
in Patients Transitioning to Dialysis
Keiichi Sumida, MD, MPH1,2,3,*, Charles Dyer Diskin, MD1,*, Miklos Z. Molnar, MD, PhD1,4, 
Praveen K Potukuchi, MS1, Fridtjof Thomas, PhD5, Jun Ling Lu, MD1, Connie M. Rhee, MD, 
MSc6, Elani Streja, MPH, PhD6, Kunihiro Yamagata, MD, PhD3, Kamyar Kalantar-Zadeh, MD, 
PhD6, and Csaba P. Kovesdy, MD1,7
1Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center, 
Memphis, TN, United States
2Nephrology Center, Toranomon Hospital Kajigaya, Kanagawa, Japan
3Department of Nephrology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
4Department of Transplantation and Surgery, Semmelweis University, Budapest, Hungary
5Division of Biostatistics, Department of Preventive Medicine, University of Tennessee Health 
Science Center, Memphis, TN, United States
6Harold Simmons Center for Chronic Disease Research and Epidemiology, Division of 
Nephrology and Hypertension, University of California-Irvine, Orange, CA, United States
7Nephrology Section, Memphis VA Medical Center, Memphis, TN, United States
Abstract
Background—Hemoglobin variability (Hb-var) has been associated with increased mortality 
both in non-dialysis dependent chronic kidney disease (NDD-CKD) and end-stage renal disease 
(ESRD) patients. However, the impact of Hb-var in advanced NDD-CKD on outcomes after 
dialysis initiation remains unknown.
Methods—Among 11,872 US veterans with advanced NDD-CKD transitioning to dialysis 
between October 2007 through September 2011, we assessed Hb-var calculated from the residual 
standard deviation (SD) of at least three Hb values during the last six months before dialysis 
initiation (prelude period) using within-subject linear regression models, and stratified into 
quartiles. Outcomes included post-transition all-cause, cardiovascular, and infection-related 
mortality, assessed in Cox proportional hazards models and adjusted for demographics, 
comorbidities, length of hospitalization, medications, estimated glomerular filtration rate (eGFR), 
type of vascular access, Hb parameters (baseline Hb [i.e., intercept] and change in Hb [i.e., 
slope]), and number of Hb measurements.
Address for correspondence: Csaba P. Kovesdy, MD, Nephrology Section, Memphis VA Medical Center, 1030 Jefferson Ave., 
Memphis, TN 38104, Phone: 901-523-8990, Fax: 901-577-7539, ckovesdy@uthsc.edu.
*K.S. and C.D.D. contributed equally to this work.
Disclosures
None of the authors have relevant conflicts of interest.
HHS Public Access
Author manuscript
Am J Nephrol. Author manuscript; available in PMC 2018 November 07.
Published in final edited form as:
Am J Nephrol. 2017 ; 46(5): 397–407. doi:10.1159/000484356.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Results—Higher prelude Hb-var was associated with use of iron and antiplatelet agents, tunneled 
dialysis catheter use, and higher levels of baseline Hb, change in Hb, eGFR, and serum ferritin. 
After multivariable adjustment, higher prelude Hb-var was associated with higher post-ESRD all-
cause and infection-related mortality, but not cardiovascular mortality (adjusted hazard ratios [95% 
CI] for the highest [vs. lowest] quartile of Hb-var, 1.10 [1.02–1.19], 1.28 [0.93–1.75], and 0.93 
[0.79–1.10], respectively).
Conclusions—High pre-ESRD Hb-var is associated with higher mortality, particularly from 
infectious causes rather than cardiovascular causes. Further research is required to clarify the 
underlying mechanisms and true causal nature of the observed association.
Keywords
hemoglobin; variability; mortality; chronic kidney disease; end-stage renal disease; transition
INTRODUCTION
Anemia is a frequent complication of chronic kidney disease (CKD) and is associated with 
worse outcomes in patients with CKD [1]. The introduction of erythropoiesis stimulating 
agents (ESAs) in 1989 has given clinicians the ability to increase hemoglobin (Hb) levels, 
yet targeting normal Hb levels did not result in better survival, but rather in increased 
cardiovascular events and mortality in patients with CKD [2–4]. Maintenance of a stable Hb 
within the narrow range currently recommended in patients with CKD often requires 
frequent ESA dosing changes that, in addition to other factors such as age, intercurrent 
diseases, and iron therapy [5,6], result in a continuous cycling of hemoglobin levels in 
contrast to individuals with normal renal function whose hemoglobin levels are held 
constant by oxygen delivery sensing feedback upon erythropoiesis. In recent years, 
observational studies have shown that higher hemoglobin variability (Hb-var) is associated 
with adverse outcomes both in non-dialysis dependent CKD (NDD-CKD) and end-stage 
renal disease (ESRD) patients [7–16]. However, to the best of our knowledge, no previous 
studies have examined the impact of Hb-var in late stage NDD-CKD on outcomes after 
dialysis initiation. Given the pervasive nature of anemia in this vulnerable population who 
experience the highest mortality immediately after the transition to dialysis and suffer from 
an exceptionally high health and economic burden [1,17], the question whether high Hb-var 
in the immediate pre-ESRD period is associated with post-transition mortality is of 
particular relevance. We therefore investigated the association of Hb-var in the pre-ESRD 
transition period with post-ESRD all-cause, cardiovascular, and infection-related mortality, 
using a large nationally representative cohort of US veterans with incident ESRD.
MATERIALS AND METHODS
Study Population
We analyzed longitudinal data from the Transition of Care in CKD (TC-CKD) study, a 
retrospective cohort study examining US veterans with incident ESRD transitioning to 
dialysis from October 1, 2007 through September 30, 2011 [18–20]. A total of 52,172 US 
veterans were identified from the US Renal Data System (USRDS) [21] as a source 
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population. The algorithm for the cohort definition is shown in Supplementary Figure 1. We 
extracted all Hb values measured during clinical encounters in any Veterans Affairs (VA) 
facility; patients without Hb measurements (n = 23,088) were excluded. We also excluded 
patients with less than three Hb measurements recorded on different days within six months 
prior to dialysis initiation (i.e., six-months “prelude period”) (n = 17,068) and who were 
missing follow-up data (n = 144), resulting in an analytical sample of 11,872 patients.
Exposure Variable
The primary exposure of interest was Hb-var over the six-month prelude period. Hb-var was 
defined as the residual standard deviation (SD) calculated by within-subject linear regression 
models using all Hb values in each patient. We categorized the Hb-var values into quartiles 
(<0.46, 0.46–<0.69, 0.69–<0.96, and ≥0.96 g/dL), using the lowest Hb-var quartile as 
reference. The Hb-var level was also treated as a continuous variable to examine nonlinear 
associations by using a restricted cubic spline analysis. Baseline Hb level and average 
change in Hb (g/dL per month) were defined as the intercept and the slope estimated from 
the same regression models used to calculate Hb-var.
Covariates
Data from the USRDS Patient and Medical Evidence files were used to determine patients’ 
baseline demographic characteristics and type of vascular access at the time of dialysis 
initiation. Information on comorbidities was extracted from the VA Inpatient and Outpatient 
Medical SAS Datasets [22], using the International Classification of Diseases, Ninth 
Revision, Clinical Modification diagnostic and procedure codes and Current Procedural 
Terminology codes, as well as from VA/Centers for Medicare and Medicaid Services (CMS) 
data. The Charlson Comorbidity Index score was calculated using the Deyo modification for 
administrative datasets, without including kidney disease [23]. Cardiovascular disease was 
defined as the presence of diagnostic codes for angina, coronary artery disease, myocardial 
infarction, or cerebrovascular disease. Medication data were collected from both CMS Data 
(Medicare Part D) and VA pharmacy dispensation records [24]. Patients who received at 
least one dispensation of medications within the six-month prelude period were recorded as 
having been treated with these medications. Laboratory data were obtained from VA 
research databases as previously described [25,26], and their baseline values were defined as 
the average of each covariate during the six-month prelude period preceding dialysis 
initiation. Estimated glomerular filtration rate (eGFR) was calculated by the Chronic Kidney 
Disease Epidemiology Collaboration equation [27].
Outcome Assessment
The co-primary outcomes of interest were all-cause, cardiovascular, and infection-related 
mortality after dialysis initiation. The start of the follow-up period was the date of dialysis 
initiation, and patients were followed up until death or other censoring events including 
kidney transplantation, loss of follow-up, or the last date of available follow-up (December 
27, 2012 and October 6, 2011 for all-cause and cause-specific mortality, respectively) [18–
20]. All-cause mortality data, censoring events, and associated dates were obtained from VA 
and USRDS data sources [21]. Cause-specific mortality data were obtained from USRDS.
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Statistical analysis
Baseline patient characteristics were summarized according to Hb-var quartiles, and 
presented as number (percent) for categorical variables and the mean ± standard deviation 
(SD) for continuous variables with a normal distribution or median (interquartile intervals 
[IQI]) for those with a skewed distribution. Differences across quartiles were assessed using 
analysis of variance and chi-squared tests for continuous and categorical variables, 
respectively. We performed multivariable linear regression to identify variables 
independently associated with Hb-var. Based on a priori knowledge and their availability in 
this study, the following explanatory variables were included: sociodemographics (age, sex, 
race, and marital status), comorbidities (diabetes mellitus, cardiovascular disease, congestive 
heart failure [CHF], peripheral vascular disease, lung disease, peptic ulcer disease, liver 
disease, malignancy, human immunodeficiency virus [HIV]/acquired immunodeficiency 
syndrome [AIDS]), Charlson comorbidity index, cumulative length of hospitalization during 
the six-month prelude period, medications (ESAs, intravenous or oral iron, vitamin D 
analogs, angiotensin-converting enzyme inhibitors [ACEIs]/angiotensin receptor blockers 
[ARBs], antiplatelet agents, and warfarin), vascular access type, baseline Hb, change in Hb, 
number of Hb measurements over the six-month prelude period, and eGFR and serum 
ferritin levels averaged over the six-month prelude period. Variance inflation factors were 
calculated to examine substantial multicollinearity among these parameters, and values >5.0 
were considered to indicate collinearity. The association between Hb-var and mortality was 
estimated using Cox proportional hazards models. Models were incrementally adjusted for 
the following potential confounders based on theoretical considerations: model 1 adjusted 
for age, sex, race/ethnicity, and marital status; model 2 additionally accounted for 
comorbidities (diabetes mellitus, cardiovascular disease, CHF, peripheral vascular disease, 
lung disease, peptic ulcer disease, liver disease, malignancy, and HIV/AIDS), Charlson 
comorbidity index, and cumulative length of hospitalization during the six-month prelude 
period as an indicator of sickness; model 3 additionally included medications (ESAs, 
intravenous or oral iron, vitamin D analogs, ACEIs/ARBs, antiplatelet agents, and warfarin), 
eGFR, type of vascular access (arteriovenous fistula, arteriovenous graft, or catheter), 
baseline Hb, change in Hb, and number of Hb measurements over the six-month prelude 
period. Tests for linear trend across quartiles were conducted by applying the median value 
of each quartile to relevant patients and modeling that variable as a continuous variable in 
the regression models. Restricted cubic spline models were used to investigate nonlinearity 
in fully adjusted associations between Hb-var and mortality.
We performed several sensitivity analyses to evaluate the robustness of our main findings. 
The associations of Hb-var with outcomes were examined in subgroups of patients stratified 
by age, race, prevalent diabetes mellitus, cardiovascular disease, and CHF, eGFR, use of 
ESAs and iron, and number of Hb measurements over the six-month prelude period. 
Potential interactions were formally tested by including relevant interaction terms. We also 
investigated whether accounting for serum ferritin levels further attenuates the Hb-var-
mortality associations in the group of 8,605 patients with available serum ferritin 
measurements as an additional model (model 4). In order to account for the different Hb 
determinations between inpatient and outpatient settings, we further performed an additional 
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analysis using at least three inpatient/outpatient Hb values separately to calculate the 
variability.
Compared to patients in the main cohort (n = 11,872), those who were excluded from the 
source cohort (n = 40,300) were older (71.6 versus 66.0 years) and were less likely to be 
male (93.3% versus 98.0%), African-American (20.9% versus 35.4%), and diabetic (53.1% 
versus 71.9%). Of the variables included in multivariable models, data points were missing 
for race (0.2%), eGFR (0.2%), vascular access type (6.4%), and serum ferritin (22.8%). 
Information about cause of death was also missing in 2,831 of the 5,711 (49.6%) who died 
in our study population (Supplementary Table 1). Of the 11,872 patients in our study 
population, 11,088 (93.4%) had complete data available for the main adjusted multivariable 
model (model 3). Due to the relatively low proportion of missingness in the main model, 
missing data was not imputed. The reported P values are two-sided and reported as 
significant at <0.05 for all analyses. All analyses were conducted using STATA/MP Version 
14 (STATA Corporation, College Station, TX). The study was approved by the Institutional 
Review Boards of the Memphis and Long Beach VA Medical Centers, with exemption from 
informed consent.
RESULTS
Baseline Characteristics
Overall, the mean±SD age at baseline was 66.0±11.1 years; 98.0% of patients were male; 
35.4% were African-American; and 71.9% were diabetic. The median (IQI) eGFR level was 
13.1 (9.9, 17.7) mL/min/1.73m2. During the six-month prelude period, patients had a 
median (IQI) of 8 (5, 15) Hb measurements. The mean±SD prelude Hb-var was 0.75±0.45 
g/dL. Baseline characteristics in the overall cohort and stratified by Hb-var quartiles are 
presented in Table 1. Compared to patients with lower Hb-var, those with higher Hb-var 
tended to have a poorer risk profile (higher prevalence of comorbidities, longer cumulative 
length of hospitalization, and lower serum albumin and higher serum ferritin levels) and had 
lower BMI and higher eGFR levels. They were also more likely to initiate dialysis therapy 
with a catheter and use ESAs, iron, and antiplatelet agents.
Variables associated with prelude Hb-var
Table 2 shows the association of Hb-var with patient characteristics. After multivariable 
adjustment, history of peptic ulcer disease or malignancy, use of iron and antiplatelet agents, 
dialysis catheter use, and higher baseline Hb, change in Hb, number of Hb measurements, 
eGFR, and serum ferritin levels were associated with higher Hb-var. In contrast, older age 
and use of warfarin were associated with lower Hb-var.
Association of Pre-ESRD Hb-var with Post-ESRD All-Cause Mortality
There were 5,711 all-cause deaths during a median follow-up of 2.1 years (IQI, 1.2, 3.3 
years; total time at risk, 26,748 patient-years) following dialysis initiation (crude incidence 
rate, 213.5 per 1000 patient-years; 95% confidence interval [CI], 208.0–219.2). Table 3 
shows the multivariable-adjusted hazard ratios (HRs) associated with pre-ESRD Hb-var 
quartiles. In the demographically adjusted model, higher Hb-var quartiles were 
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incrementally associated with higher all-cause mortality (P value for trend <0.001, Table 3). 
After further adjustment for other potential confounders, the association between Hb-var and 
all-cause mortality was substantially attenuated but remained statistically significant 
(adjusted HRs [95% CI] for quartiles 2 through 4 [vs. quartile 1], 0.99 [0.91–1.07], 1.08 
[1.00–1.17], and 1.10 [1.02–1.19], in model 3; P value for trend = 0.004, Table 3). As shown 
in Figure 1A, higher levels of Hb-var treated as a continuous variable were monotonically 
associated with higher all-cause mortality.
In subgroup analyses, higher Hb-var was associated with higher all-cause mortality across 
most subgroups (Supplementary Figure 2). Race significantly modified the association of 
Hb-var with all-cause mortality, with greater association of higher Hb-var with all-cause 
mortality among African-Americans. Results were similar after further adjustment for serum 
ferritin level and using inpatient or outpatient Hb values separately to calculate the 
variability, albeit with borderline significance (Supplementary Tables 2A–4A).
Association of Pre-ESRD Hb-var with Post-ESRD Cardiovascular and Infection-Related 
Mortality
During a median follow-up of 1.3 years (IQI, 0.6, 2.3 years) following dialysis initiation, 
1,045 and 382 deaths occurred from cardiovascular and infection-related causes, 
respectively. In the demographically adjusted model, Hb-var quartiles were incrementally 
associated with cardiovascular mortality, with significantly higher death risks seen in higher 
Hb-var quartiles. This association was considerably attenuated and no longer significant 
after further adjustment for other potential confounders (adjusted HRs [95% CI] for Hb-var 
quartiles 2 through 4 [vs. quartile 1], 0.92 [0.79–1.10], 1.03 [0.88–1.21], and 0.93 [0.79–
1.10], in model 3; P value for trend = 0.63, Table 4A). In contrast, higher Hb-var quartiles 
were associated with a trend towards higher infection-related mortality in the fully adjusted 
multivariable model (adjusted HRs [95% CI] for Hb-var quartiles 2 through 4 [vs. quartile 
1], 1.02 [0.74–1.41], 1.19 [0.87–1.63], and 1.28 [0.93–1.75], in model 3; P value for trend = 
0.079, Table 4B). When using restricted cubic spline models, there was a weak but 
nonsignificant reverse U-shaped association of Hb-var with cardiovascular mortality (Figure 
1B); while the pattern of association between Hb-var and infection-related mortality was 
qualitatively similar to that with all-cause mortality, with higher mortality seen in those with 
higher Hb-var (Figure 1C).
In subgroup analyses, the pattern of associations of Hb-var with cardiovascular and 
infection-related mortality were generally consistent across selected subgroups 
(Supplementary Figures 1B and 1C), with a few exceptions: the risk of infection-related 
mortality associated with higher Hb-var was greater in patients with eGFR <15 mL/min/
1.73m2 and those treated with ESAs, with statistically significant interactions. The 
associations were robust to additional adjustment for serum ferritin levels and when using 
inpatient or outpatient Hb values separately to calculate the variability (Supplementary 
Tables 2B–4C).
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DISCUSSION
In this large national cohort of 11,872 US veterans with advanced NDD-CKD transitioning 
to dialysis, we found that higher Hb-var was independently associated with higher all-cause 
and infection-related mortality, but not cardiovascular mortality, following dialysis initiation. 
Compared with patients in the lowest Hb-var quartile (<0.46 g/dL), those in the highest Hb-
var quartile (≥0.96 g/dL) had 10% and 28% higher all-cause and infection-related mortality, 
respectively, after adjusting for various potential confounders. During the six-month prelude 
period, we also found that history of peptic ulcer disease or malignancy, use of iron and 
antiplatelet agents, dialysis catheter use, and higher number of Hb measurements and levels 
of baseline Hb, change in Hb, eGFR, and serum ferritin were all associated with higher Hb-
var.
These results are similar to some aspects of several previous studies that reported the 
association of greater Hb-var with poor survival, almost exclusively in patients undergoing 
maintenance hemodialysis [9–16]. Recently, a few observational studies have also 
demonstrated a similar Hb-var–mortality association in NDD-CKD populations [7,8], 
suggesting its prognostic implications throughout different stages of CKD. Most 
importantly, however, no previous studies have examined the Hb-var–mortality association 
during the ESRD transition period. The extremely high mortality experienced by incident 
ESRD patients immediately following transition to dialysis [17] makes the assessment of 
modifiable pre-transition risk factors (such as Hb-var, and others) especially important in 
order to find treatment targets that might have a positive effect on their survival.
Several possible explanations have been proposed for the underlying mechanisms of high 
Hb-var, such as differences in pharmacokinetic and bioavailability parameters among drugs 
that modulate Hb synthesis (e.g., ESAs and iron) [28,29], a high number of comorbidities, 
intercurrent events, and hospitalizations [9], anemia management practice patterns, and 
reimbursement policies [30]. In line with these findings, we identified several clinical factors 
associated with higher prelude Hb-var, including history of peptic ulcer disease or 
malignancy, use of iron and antiplatelet agents, dialysis catheter use, and higher number of 
Hb measurements and levels of baseline Hb, change in Hb, eGFR, and serum ferritin. The 
substantial attenuation observed in our mortality risk estimates after accounting for all of 
these factors may, in turn, support their potential involvement as underlying 
pathophysiological mechanisms in the Hb-var–mortality relationship. In fact, patients with 
advanced NDD-CKD have an exceptionally high burden of numerous comorbidities, and 
higher prelude Hb-var may merely be a marker of more severe underlying comorbid 
conditions with concomitant chronic anemia requiring iron and/or ESAs supplementation, 
which could consequently contribute to the higher risk of all-cause mortality.
It has been suggested that increased Hb-var can also serve as a potential direct mediator of 
organ dysfunction or injury by repeated episodes of relative ischemia to vital organs and Hb 
overshoot, the former causing left ventricular dilation or hypertrophy through the 
development of pathologic changes of myocardium [31,32], the latter resulting in elevated 
blood pressure with risk for hypertensive encephalopathy [33], increased thrombotic events 
[2], and accelerated left ventricular dysfunction and hypertrophy [34], mostly in patients 
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receiving hemodialysis. In the range of Hb levels typically encountered in the NDD-CKD 
population, anemia as a cause of solid organ dysfunction mediated by ischemia would be 
unusual, which could explain why we observed less contributions of prelude Hb-var to the 
risk of cardiovascular mortality than infection-related mortality following dialysis initiation. 
This seemingly counterintuitive observation might also be partly explained by survivorship 
bias in this unique study population, such that patients who had suffered from the 
abovementioned cardiovascular complications and had higher Hb-var may have died before 
reaching ESRD.
Meanwhile, our findings on the association between Hb-var and infection-related mortality 
are generally consistent with a few previous studies that investigated the relationship 
between Hb-var and incidence of infectious diseases [9,16]. Although we cannot infer a 
causal relationship from observational studies, there are some plausible explanations linking 
higher Hb-var to the risk of infection. In the present study, despite almost identical levels of 
baseline Hb across Hb-var quartiles, we observed higher serum ferritin levels and a higher 
prevalence of patients who used iron and ESAs in higher (vs. lower) Hb-var quartiles, which 
may have reflected underlying systemic inflammation due to infections among patients with 
higher Hb-var. Increase in systemic inflammation may inhibit erythropoiesis and result in a 
blunted or absent response to ESAs despite its high-dose administration. This ESA 
hyporesponsiveness, which itself is also an independent risk factor for poor survival [35], 
may trigger the use of more iron because of the low transferrin saturation levels which result 
from inflammatory blockade of reticuloendothelial stores of iron [36]. Iron administration is 
highly effective in replenishing iron stores to accelerate erythropoiesis, but its excessive use 
may in turn result in impaired host innate immune response [37,38]. Indeed, iron overload 
has been shown to promote apoptosis of helper CD4+ T lymphocytes through iron-induced 
oxidative stress [39,40] and impair phagocytic and bactericidal capacities of 
polymorphonuclear leukocytes [41–43]; thereby increasing susceptibility to infections. 
These underlying mechanisms could synergistically contribute to a higher risk of infection-
related mortality. In our study, however, the association of Hb-var with infection-related 
mortality still remained statistically significant even after accounting for serum ferritin levels 
and use of ESAs and iron as well as various potential confounders, suggesting that higher 
prelude Hb-var could be a harbinger of future deaths from infectious causes independent of 
known risk factors. Given the considerable uncertainties about the physiological mechanism 
of Hb-var and the optimal approach to anemia management in the transition period, the 
effect of such interventions toward reducing Hb-var on patient outcomes may deserve 
further investigation.
Our study results must be interpreted in light of several limitations. First, our cohort 
consisted predominantly of male US veterans; hence, generalization of the results to women 
or patients from other geographical areas needs to be undertaken cautiously. Second, the 
effect of longitudinal changes in Hb-var and other potential confounders such as ESA use 
and iron status over the post-ESRD follow-up period was not accounted for; therefore, it is 
possible that such time-dependent factors might affect the observed associations. However, 
given the unique nature of this study which examined the impact of pre-ESRD Hb-var on 
post-ESRD outcomes, the observed results with the use of fixed prelude baseline covariates 
would still be of value, providing potential prognostic implications for post-ESRD outcomes 
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in patients with advanced NDD-CKD. Finally, as with all observational studies, we cannot 
eliminate the possibility of unmeasured confounders such as proteinuria.
In conclusion, in this large national cohort of US veterans with advanced NDD-CKD 
transitioning to dialysis, a greater pre-ESRD Hb-var was associated with higher post-ESRD 
mortality, especially with infection-related mortality. Our findings broaden the recognition 
of the prognostic importance of Hb-var in the immediate pre-ESRD period on post-ESRD 
outcomes and suggest the need for careful attention to high Hb-var in CKD patients during 
the transition period. Further research is required to clarify the underlying mechanisms and 
to test whether modification of pre-ESRD Hb-var can improve clinical outcomes in incident 
ESRD patients.
Supplementary Material
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Figure 1. Association of prelude Hb variability with (A) all-cause, (B) cardiovascular, and (C) 
infection-related mortality after dialysis initiation
Solid and dashed lines represent hazard ratio and 95% CI, respectively.
A hazard reference ratio of 1 (solid horizontal line) and a histogram of observed Hb 
variability values are overlaid.
The x-axis shows Hb variability levels, trimmed at 2% and 98%.
Model is adjusted for age, sex, race/ethnicity, marital status, comorbidities (diabetes 
mellitus, cardiovascular disease, congestive heart failure, peripheral vascular disease, lung 
disease, peptic ulcer disease, liver disease, malignancy, and HIV/AIDS), Charlson 
comorbidity index, cumulative length of hospitalization, medications (ESAs, intravenous or 
oral iron, vitamin D analogs, ACEIs/ARBs, antiplatelets, and warfarin), eGFR levels 
averaged over the six-month prelude period, type of vascular access (arteriovenous fistula, 
arteriovenous graft, or catheter), Hb variability parameters (baseline Hb level and change in 
Hb), and number of Hb measurements during the six-month prelude period.
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; AIDS, acquired 
immunodeficiency syndrome; ARB, angiotensin receptor blocker; eGFR, estimated 
glomerular filtration rate; ESA, erythropoietin stimulating agent; Hb, hemoglobin; HIV, 
human immunodeficiency virus
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Table 2
Variables associated with prelude Hb variability
Characteristics Coefficient* 95% CI P value
Age (per 1 year) −0.001 −0.002 to −0.0007   0.001
Sex (male vs. women)   0.055 −0.007 to 0.12   0.08
Race (African-American vs. white) −0.003 −0.022 to 0.017   0.79
Marital status (married vs. non-married) −0.007 −0.025 to 0.01   0.42
Comorbidities (yes vs. no)
 Diabetes mellitus −0.020 −0.047 to 0.008   0.16
 Cardiovascular diseasea   0.013 −0.009 to 0.035   0.25
 Congestive heart failure   0.002 −0.019 to 0.022   0.88
 Peripheral vascular disease   0.012 −0.008 to 0.033   0.23
 Lung disease −0.008 −0.028 to 0.012   0.42
 Peptic ulcer disease   0.047   0.012 to 0.082   0.008
 Liver disease   0.014 −0.014 to 0.042   0.33
 Malignancy   0.030   0.003 to 0.058   0.031
 HIV/AIDS   0.034 −0.046 to 0.11   0.40
Charlson Comorbidity Index (per 1 unit)   0.003 −0.004 to 0.010   0.45
Cumulative length of hospitalization (per 1 day) −0.0001 −0.0003 to 0.00008   0.27
Medications (yes vs. no)
 ESAs   0.094   0.075 to 0.113   0.27
 Iron   0.030   0.011 to 0.049   0.002
 Vitamin D analogs −0.014 −0.032 to −0.005   0.16
 ACEIs/ARBs −0.009 −0.027 to 0.009   0.30
 Antiplatelet agents   0.026   0.007 to 0.045   0.007
 Warfarin −0.052 −0.085 to −0.020   0.002
Vascular access type (catheter vs. others)   0.032   0.012 to 0.052   0.002
Laboratory parameters
 Baseline Hb (per 1 g/dL)   0.014   0.008 to 0.019   0.002
 Change in Hb (per 1 g/dL/month)   0.0004   0.0003 to 0.0007 <0.001
 Number of Hb measurements   0.006   0.005 to 0.006 <0.001
 eGFR (per 1 mL/min/1.73m2)b   0.002   0.0009 to 0.003 <0.001
 Serum ferritin (per 1 ng/mL)b   0.00010   0.00008 to 0.00012 <0.001
*Coefficient for multivariable linear regression models. Value of coefficient represents change in Hb variability (g/dL) per 1 unit change in each 
factor. Positive and negative numbers indicate higher and lower Hb variability per 1 unit change in factors, respectively. The variance inflation 
factors of these parameters were all less than 5.
aCardiovascular disease include coronary artery disease, angina, myocardial infarction, or cerebrovascular disease.
b
Laboratory results averaged over the six-month prelude period.
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; AIDS, acquired immunodeficiency syndrome; ARB, angiotensin receptor blocker; 
eGFR, estimated glomerular filtration rate; ESA, erythropoietin stimulating agent; Hb, hemoglobin; HIV, human immunodeficiency virus
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